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In this issue, Nakamura et al. (2013) describe a robust SCID mouse-based method for isolating human
monoclonal antibodies of desired specificity from adoptively transferred human B cells. As proof of principle,
they isolate humanmAbs that could potentially be used to treat or prevent human infection with any influenza
A virus strain.The evolutionary success of influenza A
virus (IAV) in humans, with its attendant
costly and deadly annual epidemics,
results primarily from the protean vari-
ability of hemagglutinin (HA), the viral
attachment and fusion protein. An enor-
mous IAV zoonotic reservoir (comprising
17 highly divergent HA subtypes) con-
stantly generates mutants with the
potential for human adaptation. Once
established in humans, rapid antigenic
evolution enables IAV to escape from
adaptive immunity, principally provided
by HA-specific antibodies (Abs) with virus
neutralizing (VN) activity. Prodded by
repeated introduction of novel zoonotic
IAV strains with the potential to repeat
the catastrophic 1918 pandemic, the
world has finally woken from decades of
complacency regarding the ineffective-
ness of IAV treatment and vaccination.
There is now the will and potentially even
the way to greatly improve IAV vaccines,
with the (re)-discovery of antibodies able
to broadly neutralize strains within and
even between IAV subtypes, kindling
hope of a ‘‘universal’’ vaccine capable of
inducing protection against all IAV
strains (http://www.niaid.nih.gov/topics/
Flu/Documents/univflu508b.pdf).
Although the first broadly neutralizing
anti-HA monoclonal Ab (mAb) was
described in 1993 (Okuno et al., 1993),
this antibody was essentially viewed as a
curiosity. Similar human mAbs were re-
ported starting in 2008, at first under the
radar (Kashyap et al., 2008; Throsby
et al., 2008) but then with increasing
fanfare as it became evident that they
point the way toward radically improved
IAV vaccines (Corti and Lanzavecchia,
2013; Wilson and Andrews, 2012). Initially
derived from combinatorial immunoglob-
ulin (Ig) gene libraries, mAbs have now
been generated from immortalized B cellclones and Ig genes cloned from
isolated B cells. Most broadly neutralizing
Abs isolated to date recognize the
conserved stem region of HA and
prevent HA-mediated viral fusion with
the target cell, but another class of Abs
insert a loop into the conserved HA re-
ceptor binding site and block attach-
ment (Ekiert et al., 2012; Schmidt et al.,
2013).
Broadly neutralizing anti-IAV Abs
potentially have important therapeutic
uses in treating severely ill patients and
in prophylaxing immunocompromised in-
dividuals. Further, understanding broad
Ab recognition of HA within and across
IAV serotypes provides the key for ratio-
nally designing immunogens that induce
such Abs. A central assumption support-
ing the utility of broadly neutralizing Abs
is that structural constraints in their epi-
topes impose sufficient fitness costs to
prevent antigenic escape. While this
remains to be directly demonstrated in
humans, it has been proposed that recog-
nition of conserved elements in the H2
HA subtypes binding site hastened
the replacement of H2 viruses with H3
viruses after only 11 years (the more
elusive H3 and H1 viruses have now
been circulating for more than 40 years)
(Xu et al., 2013).
These recent findings point to the
importance of understanding the human
Ab repertoire, not just for IAV but for other
viruses and pathogens resistant to current
vaccination efforts. In addition to possible
unique features of the human germline
repertoire, honed by eons of coevolution
with pathogens, the repertoire of indi-
vidual humans is uniquely shaped by
decades of repeated exposure to
contemporary circulating pathogens.
Although broadly neutralizing HA-specific
Abs are present in many individuals, theirCell Host & Microabundance is typically low and isolating
their producer B cells is consequently a
haystack-needle exercise.
In this issue, Nakamura et al. (2013)
transmute the needle to something
more like a rake by employing SCID/
Beige mice to enrich for human plasma-
blasts secreting broadly neutralizing HA-
specific Abs. Nearly devoid of functional
T cells, B cells, and natural killer (NK)
cells, SCID/Beige mice can be reconsti-
tuted with human cells to create a func-
tional, if imperfect human immune
system suitable for mechanistic investi-
gation. Nakamura et al. inject peripheral
blood mononuclear cells from donors
immunized 7 days previously with a stan-
dard seasonal IAV vaccine directly into
the spleens of SCID/Beige mice lightly
irradiated to create a niche for the expan-
sion of adoptively transferred cells. The
key step is to briefly incubate the trans-
ferred cells prior to injection with a
mixture of antigenically distinct HAs
(from the vaccine administered to the do-
nors) to selectively activate broadly
crossreactive B cells. After 8 days in
mice, human plasmablasts now consti-
tute up to 20% of the splenocyte popula-
tion, and can be flow-cytometry sorted
based on their simultaneous binding to
a pair of widely divergent HAs labeled
with different fluors. Nakamura et al.
then employed standard PCR and clon-
ing technology to isolate Ab genes from
single cells and express the genes in
transfected cells for testing their cross-
reactive recognition across widely dispa-
rate HA subtypes.
Through this relatively simple and
inexpensive method (compared to previ-
ous methods, which required heroic
screening efforts to identify Abs at fre-
quencies of one in a hundred-thousand
to million), Nakamura et al. (2013)be 14, July 17, 2013 ª2013 Elsevier Inc. 7
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that are able to bind each of 4 HA sub-
types tested. Two mAbs neutralize vi-
ruses with either human (H1, H2, H3) or
avian (H5, H7) HAs. These are among
the few mAbs described with such broad
neutralization profiles, which could poten-
tially be used clinically for IAV infections in
humans. X-ray crystallography of one of
these mAbs revealed binding to an
epitope in the stem region bound by the
original mouse broadly neutralizing Ab
and most human stem-reactive neu-
tralizing Abs.
Notably, each of the solved structures
reveals differences in Ab orientation,
contribution of heavy and light chains to
binding energy, and particularly dealing
with N-linked oligosaccharides, that are
present in this region among many
different HA subtypes. Remarkably, the
mAb studied by Nakamura et al. (2013)
actually contacts an HA oligosac-
charide, which makes the oligosaccha-
ride part of the epitope. This raises the
immediate question of how this mAb
deals with the many potential structural
differences in this oligosaccharide when
HA is expressed in different host cells
(the insect cells used to produce the
HA for structural studies can only syn-
thesize simple N-linked oligosac-8 Cell Host & Microbe 14, July 17, 2013 ª201charides, unlike cells from vertebrate or-
ganisms), and the longer-term question
of whether IAV will manipulate stem
N-linked oligosaccharides to escape
stem-based neutralizing Abs, and what
fitness costs this will entail (Das et al.,
2011).
While these questions are important for
IAV passive and active vaccination, they
should not overshadow the central
achievement of Nakamura et al. (2013) in
providing a robust method for isolating
human mAbs. One of the major chal-
lenges facing infectious disease research
is to better tap the potential of Abs, and in
particular to not be swayed by the proper-
ties of polyclonal serum antibodies, which
reflect the net effects of Abs with a wide
divergence of functional activities.
Although we are approaching the 40th an-
niversary of mAb technology, we know
remarkably little about the synergistic
versus antagonistic effects of Abs specific
for the same antigen and how this affects
net Ab effector function in vivo. Fortu-
nately for infectious disease research,
the fickle interest of adaptive immunolo-
gists has swung from T cells back toward
B cells and Abs, which still offer the best
vaccine targets against many of the high
hanging fruit-pathogens that plague
mankind.3 Elsevier Inc.REFERENCES
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